Cantor Fitzgerald Predicts EYPT FY2026 Earnings

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Cantor Fitzgerald issued their FY2026 earnings estimates for shares of EyePoint Pharmaceuticals in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst J. Kim anticipates that the company will earn ($2.35) per share for the year. The consensus estimate for EyePoint Pharmaceuticals' current full-year earnings is ($2.13) per share.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.65). The business had revenue of $24.50 million during the quarter, compared to analysts' expectations of $8.84 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%.

Other equities analysts have also issued reports about the company. Mizuho reduced their price target on EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a research report on Friday, May 16th. HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, May 29th. Wall Street Zen upgraded EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. Finally, Chardan Capital dropped their target price on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, EyePoint Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $25.38.

EyePoint Pharmaceuticals Stock Performance

Shares of NASDAQ:EYPT traded up $0.05 during midday trading on Tuesday, hitting $8.86. 789,099 shares of the company's stock traded hands, compared to its average volume of 817,359. EyePoint Pharmaceuticals has a twelve month low of $3.91 and a twelve month high of $13.99. The company has a market cap of $609.67 million, a PE ratio of -4.43 and a beta of 1.61. The firm's fifty day moving average price is $6.36 and its two-hundred day moving average price is $6.93.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC grew its position in EyePoint Pharmaceuticals by 410.4% in the third quarter. Barclays PLC now owns 245,045 shares of the company's stock worth $1,959,000 after buying an additional 197,033 shares during the last quarter. abrdn plc bought a new position in shares of EyePoint Pharmaceuticals in the fourth quarter valued at approximately $1,719,000. Rhumbline Advisers increased its stake in shares of EyePoint Pharmaceuticals by 16.1% in the fourth quarter. Rhumbline Advisers now owns 89,560 shares of the company's stock worth $667,000 after purchasing an additional 12,443 shares during the period. Bank of New York Mellon Corp grew its holdings in EyePoint Pharmaceuticals by 22.2% in the 4th quarter. Bank of New York Mellon Corp now owns 204,260 shares of the company's stock valued at $1,522,000 after buying an additional 37,054 shares during the last quarter. Finally, Levin Capital Strategies L.P. increased its position in EyePoint Pharmaceuticals by 440.0% during the fourth quarter. Levin Capital Strategies L.P. now owns 54,000 shares of the company's stock worth $402,000 after acquiring an additional 44,000 shares during the period. Institutional investors and hedge funds own 99.41% of the company's stock.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.